Various nomograms have also been established to predict the survival outcomes for EGFR positive NSCLC patients, and it has been found that IHC biomarkers play an important role in predicting the survival of patients and efficacies of EGFR-TKIs (19, 20, 23–25). This evidence concerns the gene EGFR and non-small cell lung carcinoma.